Court Sees Infringement Of Allergan Glaucoma Patent

Law360, New York (October 23, 2009, 7:47 PM EDT) -- A federal court ruled Friday that two generic-drug makers violated patents held by Allergan Inc. for glaucoma treatments using brimonidine.

The U.S. District Court for the District of Delaware found in products proposed by Apotex Inc. and Excela PharmSci Pvt. Ltd. infringe the asserted claims of Allergan's patents and that the patents were valid and enforceable.

Allergan uses brimonidine tartrate in its drug Alphagan P, an ophthalmic solution for the treatment of glaucoma.

The company holds five patents for the treatment, which was developed by Drs....
To view the full article, register now.